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The vascular endothelial growth factor receptor 2 (VEGFR-2) is a tyrosine kinase receptor, expressed primarily in endothelial cells, 
and is activated by the specific binding of VEGF to the VEGFR-2 extracellular regulatory domain. Once activated, VEGFR-2 undergoes 
autophosphorylation, triggering signaling pathways leading to endothelial cell proliferation and subsequent angiogenesisY1 Small 
molecules may act as inhibitors by competing for the ATP-binding s'1te of the VEGFR-2 intracellular tyrosine kinase domain, thereby 
preventing the intracellular signa ling that leads to angiogenesis. [ZJ 
Here, we present the synthesis of new 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas la-c, as potent type 11 VEGFR-2 
inhibitors based on molecular docking (Figure A) and biological evaluation including enzymatic assays using the VEGFR-2 tyrosine kinase 
domain (ICso=l0-28 nM) and studies in human umbilical vein endothelial cells (HUVECs). The latter included cell viability (MTS), 
proliferation (BrdU) and Western blot for total and phosphorylated VEGFR-2 (Figure B). 
The predicted docked poses were analyzed in detail and a plausible explanation for compounds 1 potency was obtained base9 on 
the simultaneous presence of a S-linker and the arylurea moiety in the meta position as a new substitution pattern for the type 11 
VEGFR-2 inhibitors. These chemical features place the thieno[3,2-b]pyridine and the terminal aryl ring in close superimposition to a 
pyrrolo[3,2-d]pyrimidine derivative. The presence of hydrofobic substituents (F and Me) in the terminal aryl ring is also important. For 
these compounds a significant inhibition in HUVECs proliferation upon VEGF stimulation was observed at low concentrations (0.5-1.0 
IJ.M) without affecting 
cell viability. Western-
blot analysis 
demonstrated that 
compounds 1 
significantly 
the 
inhibited 
VEGFR-2 
phosphorylation at 
1.0 jlM, thus confirming 
their anti-angiogenic 
potential. 
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Mammalian target of rapamycin (mTOR), a 289 kDa serine/threonine kinase of the phosphoinositide 3-kinase-like 
:entral regulator of cell growth and proliferation. Mutations and dysregulation of the PJ3K/mTOR pathway (amplification 
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